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Abstract 
 
The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 
chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the entire human 
genome. Mutations in this gene cause Duchenne and Becker Muscular Dystrophy, X-linked Dilated 
Cardiomyopathy, and other milder muscle phenotypes. Beside the remarkable number of reports 
describing dystrophin gene expression and the pathogenic consequences of the gene mutations in 
dystrophinopathies, the full scenario of the DMD transcription dynamics remains however, poorly 
understood. Considering that the full transcription of the DMD gene requires about 16 hours, we 
have investigated the activity of RNA Polymerase II along the entire DMD locus within the context 
of specific chromatin modifications using a variety of chromatin-based techniques. 
Our results unveil a surprisingly powerful processivity of the RNA polymerase II along the entire 
2.2 Mb of the DMD locus with just one site of pausing around intron 52. We also discovered 
epigenetic marks highlighting the existence of four novel cis-DNA elements, two of which, located 
within intron 34 and exon 45, appear to govern the architecture of the DMD chromatin with 
implications on the expression levels of the muscle dystrophin mRNA.  
Overall, our findings provide a global view on how the entire DMD locus is dynamically 
transcribed by the RNA pol II and shed light on the mechanisms involved in dystrophin gene 
expression control, which can positively impact on the optimization of the novel ongoing 
therapeutic strategies for dystrophinopathies. 
 
KEY words: dystrophin;  Duchenne Muscular Dystrophy (DMD);  Becker Muscular Dystrophy 
(BMD);  Transcriptional Regulation;  Chromosome. Conformation Capture (3C); RNA Pol II 
Pausing. 
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1. Introduction 
 
Mutations in the dystrophin gene (DMD) cause Duchenne Muscular Dystrophy (OMIM *310200), 
an X-linked muscle disorder, characterized by the complete absence of the dystrophin protein. 
Milder allelic forms are both the Becker Muscular Dystrophy (BMD, OMIM *300376), presenting 
a disease course mitigated by the presence of a residual Dystrophin expression, and the X-linked 
dilated cardiomyopathy (XLDC, OMIM *302405) characterized by predominant heart involvement. 
Other allelic milder disorders such as quadriceps myopathy and isolated high CK can also occur. 
The DMD gene consists of 79 exons and 78 introns encoding for at least seven distinct isoforms, 
whom transcription is driven by seven different promoters. Moreover, such promoters have a tissue- 
and time-specific regulation [1]. Three of them drive the transcription of full-length isoforms that 
share 78 exons, but with one first exon that is unique to each isoform. The three full-length isoforms 
are named Dp427b, Dp427m and Dp427p, where b-brain, m-muscle and p-purkinje indicate the 
tissue specificity or prominent expression of their synthesis: brain (cerebral cortex and 
hyppocampus), striated muscle (including skeletal and cardiac muscle) and cerebellum Purkinje 
cells respectively. Nevertheless, Dp427b shows ectopic expression sites, and is present in some 
brain compartments as well as in the heart, the Dp427m is expressed in the muscle and heart, 
whereas the Dp427p is exclusively present in brain, depending on the developmental stage [1]. 
Furthermore, other four promoters have been recognized to drive short DMD isoforms. The 
promoters are localized within intron 29 (retinal isoforms or Dp260, R), intron 44 (Brain specific 
isoform or Dp140, B3), intron 55 (Schwann cells isoform or Dp116, S) and intron 62 (General 
isoform or Dp71, G) [2]. 
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The large genomic size of DMD is due to the presence of extremely large introns, which account for 
roughly 99% of DMD genomic locus [3].  
For all these variegated reasons, the transcription of the DMD locus is known to be a very complex 
process, which remains however, poorly understood. This is somehow surprising considering that in 
the last years, novel therapies have emerged to treat DMD, acting on splicing modulation or 
translation modification [4, 5] and there is no doubt that these therapeutic protocols would 
tremendously benefit from a deeper understanding of the transcription and splicing regulatory 
mechanisms the DMD locus undergoes. Nonetheless, relatively few studies were published about 
DMD transcription regulation. Among these, Tennyson et al. evaluated the time required to 
complete DMD gene transcription, being 16 hours [6]. Studies carried out in mouse (in vivo) and 
human skeletal muscles (in vitro) identified one enhancer element, named Dystrophin muscle 
enhancer-1 (DME-1) [7, 8] which shows a specific tissue regulation, exerting its activity only on the 
Dp427m isoform expressed in skeletal muscle [9], through specific DNA sequences [10] and 
specific muscle transcription factors such as MyoD [11]. More recently, it has been shown that 
Dystrophin production is under the control of a variety of RNA molecules (miRNAs or lncRNAs). 
Among these, some miRNAs, named dystromirs, can regulate Dystrophin expression in trans, by 
acting via binding to the 3’UTR regions of the cognate transcript, and are increased in patients’ 
muscle and plasma, possibly representing prognostic biomarkers [12]. In addition to that, we have 
also recently identified five novel long non-coding RNAs, transcribed inside the DMD locus that 
downregulate the basal transcription status of dystrophin [13]. Even more recently, the dystrophin 
splicing has been finely studied and recursive multistep splicing occurs, as a further demonstration 
of the complex regulation of the processing of this extremely large gene [14]. 
The long DMD locus transcription timing (16 hours) suggests that mechanisms through which RNA 
polymerase II accomplishes this task might be very complex.  For instance, it is not entirely known 
the set of cis and trans regulatory elements that control transcription from the many dystrophin 
promoters. Furthermore, it is not clear whether RNA pol II proceeds at a constant pace over the 2,2 
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Mb region or instead pauses at specific sites and whether these pausing sites are functional to the 
proper maturation of the dystrophin transcripts as recently observed for genes in yeast [15]. 
Based on these premises, we have analyzed the activity of RNA pol II during the transcription of 
the dystrophin gene using a ChIP-chip approach. Moreover, the major modifications of the RNA 
pol II CTD (carboxyl-terminal domain) (phosphorylation on Serine 5 and/or Serine 2) suggestive of 
transcript elongation or pausing were monitored and correlated with the chromatin context.  
Our findings unveil a surprisingly powerful processivity of the RNA pol II along the entire 2.2 Mb 
of the DMD locus with just one site of pausing in intron 52. More importantly they highlighted the 
existence of remarkable cis-DNA elements within the body of the DMD gene that govern the 
architecture of the DMD locus. Our report, for the first time, describes novel cis-acting regulatory 
elements required for dystrophin expression, with a potential repercussion on the optimization of 
novel therapies.  
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2. Materials and Methods 
 
2.1 Cell cultures and treatments: Human rhabdomyosarcoma SJCHR30 cells were cultured in 
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) and 50 mg/ml 
gentamycin and grown at 37 ºC and 7% CO2. Human HeLa cells were cultured in Dulbecco's 
modified Eagle's medium containing 10% heat-inactivated FBS and 50 mg/ml gentamycin and 
grown at 37 ºC and 5% CO2. 5,6-Dichlorobenzidazole 1-beta-D ribofuranoside (DRB) was 
purchased from Sigma-Aldrich and cells were treated for 6h at 100mM before performing 
quantitative ChIP (qChIP). C2C12 cells were grown in Dulbecco's modified Eagle's medium 
containing 25 mM glucose 20% heat-inactivated FBS and 50 mg/ml gentamycin at 37 ºC, at 5% 
CO2. 
 
2.2 qChIP: ChIP was performed as previously described [16]. The antibodies employed in this 
study were: Anti-RNA polymerase II Abcam (ab76123), Anti-RNA polymerase II CTD repeat 
YSPTSPS (phospho S2) Abcam (ab5095), Anti-RNA polymerase II CTD repeat YSPTSPS 
(phospho S5) Abcam (ab5131), Anti-Acetyl Histone H3 Upstate (06-599), Anti-Dimethyl Histone 
H3 (Lys4) Upstate (07030), Anti-Trimethyl Histone H3 (Lys 36) Abcam (ab9050).   
Specific pairs of primers used for qChIP are listed in Supp. Table 1. Dual ChIP assays were 
performed as described [17]. 
 
2.3 ChIP on chip: Design of the chip array.  DMD-ChIP microarray design was performed using 
the web based Agilent eArray database version 4.5 (Agilent Technologies, Santa Clara, CA). The 
high density of a CGH search function within eArray was used to turn the genomic region into a 
probe set by selecting the maximum number of 60mer oligonucleotide ChIP probes available in the 
database. This probe set included 28086 probes that were enriched with 12000 probes from the 
High density Agilent database covering the DMD locus and 2076 probes, replicated to fill the array, 
from the genes selected as controls (Myoglobin, neurotrophic tyrosine kinase receptor, protein 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 7 
kinase C substrate 80K-H isoform 1, Homo sapiens primary neuroblastoma cDNA and Creatine 
Kinase) to reach the array format of 4 × 44 K, creating four identical 44 K arrays on a single slide 
for simultaneous analysis of four different samples. 
Immunoprecipitated DNA from ChIP was amplified with GenomePlex® Whole Genome 
Amplification (WGA) Kit according to manufacturer's instructions. Labelling and hybridisation 
were performed following the protocols provided by Agilent (Agilent Oligonucleotide Array-Based 
CGH for Genomic DNA Analysis protocol v5.0). The array was analysed with the Agilent scanner 
and the Feature Extraction software (v9.1). A graphical overview and analysis of the data were 
obtained using the Agilent Genomic Workbench software (v7.0.4). Row data were statistically 
analysed by using Blank Subtraction and Variance stabilization algorithm (Agilent Technologies) 
for data normalization, Whitehead Per-Array Neighbourhood Model and Whitehead Error Model 
method algorithms for peak detection and statistical significance (Agilent Technogies).  
The full microarray data has been deposited in the NCBI GEO as series GSE66571. 
 
2.4 Cloning and Luciferase assay: The pGL3-basic and Renilla-TK vectors were obtained from 
Promega. The promoter regions of the Dp427m isoform along with those corresponding to intron 52 
or exon 62 were obtained using PCR and cloned into the pGL3-basic vector. Specific primer pairs 
are listed in S1 Tab. The activity of firefly or Renilla luciferase was measured with a dual luciferase 
assay kit (Promega) according to the instructions. 
 
2.5 Chromosome Conformation Capture: 1 × 107 cells were resuspended in 10 ml 1X PBS 
supplemented with 10% FBS and incubated with 1% formaldehyde for 10 min at room temperature. 
To stop formaldehyde crosslinking reaction, 0,5ml of 2,5M Glycine were added and cells were 
incubated on ice for 10 min. Cells were spun at 225g for 8 min and pellet was incubated on ice for 
20 min with 5 ml of Cell Lysis buffer (10mM Tris-HCl Ph8; 10mM NaCl; 5mM MgCl2; 0,1mM 
EGTA; 1X complete protease inhibitor, Roche). After centrifugation (10 min at 800g) nuclei were 
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collected and resuspended in 0,6 ml of 1,13X NEB buffer 4+BSA. Nuclei were incubated with 
0,3% SDS for 1h at 37 ºC while shaking at 900 rpm, than Triton X-100, they were added to a final 
concentration of 2% and nuclei were incubated for 1h at 37 ºC while shaking at 900 rpm. 800 U of 
XbaI restriction enzyme were added and the reaction was incubated overnight at 37 ºC at 900 rpm.  
The day after, digested nuclei were incubated 1,6% SDS at 65ºC for 25 min at 900 rpm. After SDS 
incubation, digested nuclei were re-suspended in 6 ml of 1X NEB T4 ligase buffer and incubated 
with 1% Triton X-100 for 1h at 37ºC with gently shaking. Then, nuclei were incubated with 300 U 
NEB T4 ligase for 6 hours at 16°C. After ligation, cross-linking was reversed by incubation with 
130 mg Proteinase K (Roche) at 65ºC o/n. DNA was purified by Phenol/Chloroform/Isoamyl 
extraction, ethanol precipitated. As negative controls, non cross-linked cells were used. qPCR 
(TaqMan® Environmental Master Mix 2.0, Life-Technologies) with primer pairs and probes (Tab 
S1) specifically amplifying the looped product as well as the control product was performed 
according to manufacturer's instructions. Moreover, intra and extra chromosomal negative controls 
were used. For each amplicon, the qPCR reactions were terminated when the samples with lowest 
threshold cycle number were in the late exponential phase and loaded on agarose gels for relative 
quantification of specific amplicons. 
 
2.6 Patients: A total of nine patients with Becker muscular dystrophy were selected from a cohort 
using as inclusion criteria the presence of deletion mutations comprising exons 34, 45, 34–45 or 
none of these regions. In the BMD patient with a 13-34 deletion, the intron-34 breakpoint was distal 
to the DMI34 region, assessed by PCR analysis. A muscle from a healthy subject was used as a 
control. Skeletal muscle biopsies were obtained from the Telethon Biobank of the C. Besta 
Neurological Institute of Milan (Italy).  
 
2.7 Protein analysis by Western Blotting: For Western blotting analysis, proteins were 
homogenized from either snap frozen muscle tissue or cryostat cut sections as reported by Anthony 
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et al [18].  An amount of 40-60 g of total proteins was loaded onto a 6% polyacrylamide gel and 
transferred onto nitrocellulose membranes. Membranes were incubated overnight at 4°C with Dys2 
(1:50, Leica) and sarcomeric alpha-actinin (as a loading control, 1:7500, Sigma) primary antibodies. 
After several washings, membranes were incubated for 1 hour with secondary antibodies:  anti-
mouse IR800 (for dystrophin detection, 1:15000, Licor) and anti-mouse IR680 (for alpha-actinin 
detection, 1:15000, Licor). Membranes were imaged using a LiCor Odyssey scanner. For 
quantification, dystrophin intensity was normalized to alpha-actinin using ImageJ software and 
expressed as a percentage of control. 
 
2.8 DMD Gene Micro Fluidic Card (FluiDMD) Analysis: Total RNA was isolated from muscle 
samples using the RNeasy Kit (Qiagen, Valencia, CA).  Before cDNA synthesis, RNA was pre-
treated with DNAse I (Roche, Branford, CT) and checked for residual DNA contamination by a 55-
cycle PCR. All transcripts originating from the DMD locus were explored using a slightly modified 
design of previously reported Micro-Fluidic Card [19]. Briefly, 250 ng of RNA from each sample 
were retrotranscribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem, 
Foster City,CA) in a volume of 20 μl, according to the manufacturer instructions To this quantity 
100 ml of 2× Universal Master mix (Applied Biosystem) and 80 μl of sterile water were added. 
100μl per port of the resulting mixture were loaded onto the fluidic cards, which were run on a 
Real-Time 7900HT appliance (Applied Biosystem). Evaluation of all transcripts originating from 
the DMD locus compared with ACTB, used as endogenous control, and relative quantification were 
performed by the comparative CT method (∆∆CT Method; Applied Biosystem User Bulletin #2). A 
variation in the representation of an exon junction was evaluated by subtracting the CT of each 
system from ACTB system in both the test and control samples. The total ∆CTs in the test sample 
thereby obtained were subtracted from the corresponding ∆CTs in the control sample. Thus, the 
amount of each exon junction was given by the ∆∆CTs of a single system elevated by 2–∆∆CT. 
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2.9 Bioinformatics analysis of the DMI52 region  
We performed TF motif finding using LASAGNA (Length-Aware Site Alignment Guided by 
Nucleotide Association, http://biogrid-lasagna.engr.uconn.edu/lasagna_search) algorithm. We 
intentionally restricted the TF search to Vertebrate TRANSFACT matrices collection.  
To sort for TFs expressed in human rhabdomyosarcoma SJCHR30 cells, we retrieved RNA-seq data 
available in the gene quantification tables from 2 biological replicates loaded in the processed data 
section of the ENCODE project ENCSR568YRP 
(https://www.encodeproject.org/experiments/ENCSR568YRP). To convert the ENSEMBL genes 
ID to HGNC symbol (HUGO Gene Nomenclature Committee), we employed BIOMART 
(www.ensembl.org/biomart/martview). We arbitrarily defined “expressed” a gene showing the 
FPKM (fragment per kilobase of exon per million fragment mapped) value >10. The list of 115 
putative TFs was merged with the list of 7165 expressed genes in SJCHR30 cells by using Galaxy 
(https://usegalaxy.org). The merge retrieved 37 human TFs expressed in rhabdomyosarcoma 
SJCHR30 cells. Gene Set Enrichment Analysis was performed with GSEA software 
(http://www.broadinstitute.org/gsea/index.jsp) on expressed TFs. Gene set represented by expressed 
TFs gave raised to Reactome pathways derived from the Molecular Signatures Database 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp). A gene interactions network among the 
expressed TFs was mapped using the web-available software STRING (http://string-db.org). 
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3. Results 
 
3.1 Mapping RNA Polymerase II activity along the DMD locus through a ChIP-chip approach 
 
To understand the dynamics of how the RNA polymerase II (RNA-Pol II) transcribes the DMD 
locus we adopted a ChIP-chip approach. The RNA Pol II binding to DNA along its functional 
modifications in the Carboxyl-Terminal Domain (CTD) were correlated with histone marks such as 
Ac-H3, H3K4me2, which characterize the open chromatin of genes actively transcribed. As a cell 
system, we used SJCRH30, a human rhabdomyosarcoma cell line which derives from a male 
striated muscle tumor and maintains the several features of differentiated muscle cells, such as for 
instance expression of the muscle and brain dystrophin isoforms (Dp427b and Dp427m) [20] with 
levels comparable to that of GAPDH, an housekeeping metabolic gene whose expression is often 
used as a reference in mRNA quantitation assays (Fig. S1).  As a negative control we used instead 
HeLa cells which, with the sole exception of the ubiquitous Dp71 mRNA, do not express any 
muscle/brain dystrophin transcripts (Fig. S1). The immune-precipitated DNA was, then, hybridized 
to a DMD locus specific custom-made chip array. ChIP on chip row data were statistically analysed 
as described in materials and methods. Results showed that RNA pol II was strongly associated 
with the promoter regions of Dp427b, Dp427m, and Dp71 isoforms in SJCRH30 cells, but, as 
expected, not with that of the Dp427p isoform, which is not expressed in this cell line (Fig. 1A and 
Fig. S2A). Consistently, RNA pol II was associated with the promoter of the Dp71 isoform in HeLa 
cells only (Fig. 1B and Fig. S2B). Furthermore, phospho-Ser2 and phospho-Ser5 of the RNA pol II 
CTD were enriched throughout the first exon of each isoform while the phospho-Ser2 mark 
increased at the distal regions downstream the transcription start site, to indicate that we could 
specifically detect both the initiating and elongating RNA pol II. As expected, the same regions 
bound by the RNA pol II were also characterized for strong presence of pan-H3ac and H3K4me2 
histone modifications typical of the open chromatin of active promoters.  
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Fig. 1. Distribution of RNA polymerase II and chromatin marks along the DMD locus. ChIP-on-chip analysis in 
SJCRH30 and HeLa cells with anti-PolII, anti-CTD-pSer2, anti-CTD-pSer5, anti-H3ac and Anti H3K4me2 on DMD 
locus. A-B) Graphical representation of ChIP-chip enrichments of promoter/first exon of Dp427b, Dp427m, Dp427p 
and Dp71 DMD isoforms aligned to their chromosomal position. C-D) Alignment of Intron 52 and Exon 62 of Dp427m 
to their chromosomal position. E-F) Graphical representation of ChIP-chip enrichment on Intron 34 and Exon 45 of 
Dp427m isoform. A more detailed definition of the chip probes that were significantly hybridized by the ChIP-DNA are 
described in Figure S2 (SJCRH30) and S3 (HeLa). Raw data were normalized by blank-subtraction and variance 
stabilization. Statistically significant enriched probes (red square) were identified by Whitehead Error Model. 
Whitehead neighbourhood model was used to detect peaks (yellow box). 
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Aside from these observations, which were somehow expected, we also found additional four DNA 
regions inside the DMD locus that resulted positive for some of the markers analyzed. First, the 
RNA Pol II was strongly bound to two regions: one inside intron 52 (DMI52) and another one 
around exon 62 (DME62) (Fig. 1C and Fig. S2C). The fact that both regions were also marked for 
presence of RNA pol II p-Ser2, p-Ser5, H3ac, H3K4me2 suggested that these two regions might 
correspond to regulatory elements in proximity of putative transcription start sites. These two 
regions appear to function in muscle like cells only, for the markers were absent in HeLa cells 
(Fig.1D and Fig. S3A ). Furthermore, in SJCRH30, two additional DNA regions in intron 34 
(DMI34) and in exon 45 (DME45) were also found for presence of pan-H3ac and H3K4me2 but not 
of the RNA Pol II (Fig. 1E and Fig. S3B), and again absent in HeLa cells (Fig 1F and supp. Fig 3C). 
This suggested that the latter two DNA regions may play some sort of muscle specific function 
which is independent from the RNA Pol II activity. 
3.2 Function of DMI52 and DME62 regions 
 
The fact that RNA pol II associates with DMI52 and DME62 suggested that these regions might 
correspond to either novel transcription start sites or pausing sites. To address this issue, we first 
validate ChIP on chip data by performing ChIP in SJCRH30 and analyzing the association and 
distribution of RNA pol II and related CTD modifications along the two DNA sites. Results in Fig. 
2 (-DRB panel) show that, indeed these two regions were bound by RNA pol II. To discriminate 
whether the regions were involved in de novo transcription or pausing we performed ChIP on cells 
pretreated with 5,6-Dichlorobenzidazole 1-beta-D ribofuranoside (DRB), an RNA Polymerase II 
inhibitor, which prevents the polymerase to switching from the stalled to a processive conformation 
[21]. Indeed, following treatment, only the transcriptional start sites should be enriched by RNA 
Polymerase II, since a hypothetical pausing site would be depleted of a processive polymerase. As a 
corroborating control of that, the promoter region of the GAPDH gene that is actively and 
constitutively transcribed in these cells, was also analyzed. 
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Fig. 2. DMI52 carries a genuine RNA pol II pausing site. Chromatin immunoprecipitation analysis of Exon 62 and 
Intron 52 of Dp427m was carried out before and after treatment with 100µM of 5,6-Dichlorobenzimidazole riboside (a 
RNA Polymerase II inhibitor) for 6h in SJCRH30 cells. Chromatin was immunoprecipitated using antibodies against 
PolII, CTD-pSer2 and CTD-pSer5. GAPDH first exon was used as a control. Error bars indicate S.E. 
 
As shown in Fig. 2 (+ DRB panel), we observed depletion of RNA Pol II from the Intron 52. In 
order to rule out that the result depended on a reduced expression of Polymerase, as a consequence 
of the inhibitor treatment, we determined the RNA Pol II levels by Western blotting. Results show 
that the RNA pol II levels are not affected by DRB (Fig. S4), thereby confirming that this region 
may represent a genuine pausing site for the polymerase during the transcription of Dp427m or 
Dp427b mRNAs. In contrast, the RNA polymerase was still present on Exon 62. Particularly, the 
enrichment was observed for Pol II and CTD-P-Ser5-Pol II but not for CTD-P-Ser2-, indicating that 
the region may be associated with a novel transcription start site. Indeed, both bioinformatics 
assembly of annotated ESTs (Supp. Fig. 5) and RT-PCR (Supp. Fig. 6) revealed the existence of a 
novel mRNA, which starts from the inner region of exon 62 with the same orientation of the Dp427 
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transcripts. Bioinformatics analyses suggest that this is a non-coding RNA since no ORFs of 
adequate size were predicted.  
 
3.3 Bioinformatics analysis of the DMI52 region  
The DMEI52 pausing site was analyzed for the presence of putative transcription factor binding 
sites (TFBS). LASAGNA webtool [22] scored 228 Vertebrate TRANSFAC matrices (Table S2) To 
sort for TFs expressed in human rhabdomyosarcoma SJCRH30 cell line [23] we merged the TFs 
with the RNA-seq gene expression data available in SJCRH30 cells (ENCODE project 
ENCSR568YRP). The search for transcription factors expressed in rhabdomyosarcoma SJCRH30 
cell line gained a gained a list of 37 human TFs (Table S3). 
GSEA (Gene Set Enrichment Analysis) analysis [23] on 37 expressed TFs scored 10 Reactome 
pathways containing transcription factors involved in myogenesis (as MYOD1, MEF2A, MYOG) 
and signaling proteins (ELK1, ATF2, JUN) (Table S4). This is consistent with the DMI52 function 
as pausing site in dystrophin gene, which is almost exclusively expressed in muscle (both striated 
and cardiac). Interestingly also circadian clock related proteins are represented in the Reactome 
pathways, reinforcing the link between muscle differentiation or regeneration and synchronization 
as already published. STRING analysis (http://string-db.org) [24-26] of network nodes involving 
the scored 37 human TFs identified experimentally determined interaction among the TFs 
supporting the bioinformatics analysis performed on DMI52 pausing site (Fig S7). 
 
3.4 Function of DMI34 and DME45 regions. 
 
Since in SJCRH30 cells, DMI34 and DME45 were strongly marked by H3K4me2, pan-acetylation 
and more precisely by acetylation of H3K27, a specific marker of enhancer elements (Fig. S8), we 
speculated that these regions might function as regulatory elements possibly with enhancer-like 
activities. To support this idea, the two DNA regions were separately cloned in both directions into 
a reporter vector downstream the luciferase reporter whose activity was driven by the upstream 
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Dp427m promoter. Constructs were transiently transfected in SJCRH30 and murine C2C12 cells 
and luciferase activity was monitored at 24 hours from transfection. Results showed that DMI34 
can stimulate the Dp427m promoter transcription when cloned in both directions and predominantly 
in the inverse one (Fig. 3A). In contrast, DME45 showed very low effect or at most had a negative 
impact on the transcription of the reporter particularly in the C2C12 cells (Fig. 3B).  
 
 
Fig. 3. DMI34 displays an enhancer-like activity in a Luciferase reporter assay. Dp427m intron 34 and exon 45 
were cloned into a reporter vector (luc-reporter) downstream the luciferase gene transcribed by Dp427m promoter. 
Constructs were tested in SJCRH30 and C2C12 cells 24h from transfection. A renilla reporter cotransfected with each 
Luc reporter was used to normalize luciferase activity. Results are the mean +/- SE of 3 independent transfections in 
triplicates. A t-student test was applied to determine statistically significant differences among tested conditions  
(* indicates  p<0.05; n.s., non-significant) 
 
Although the luciferase assay was informative, results could not take into account the chromosomal 
distances between the DMI34/DME45 regions and the Dp427m promoter; it is known that several 
transcriptional enhancers can work several tens or hundred thousands bps from their target sites 
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[27]. To demonstrate in vivo physical association of the intron-34/exon-45 regions with the 
Dp427m promoter we applied a Chromosome Conformation Capture (3C) assay on SJCRH30 and 
HeLa cells. Schemes of the experimental design of the assay are described in Figs. 4A and 4D. 
Results show that DMI34 could generate a DNA PCR product specifically resulting from the 
natural juxtaposition of DMI34 with the Dp427m promoter (Fig. 4B). As expected no PCR product 
was observed in HeLa cells in which the Dp427m isoform is not expressed. (Fig. 4C). Furthermore, 
no PCR products were observed when DMI34 was tested for interaction with other in cis 
(chromosome Xq22 and Xp22) or in trans chromosomal domains (chromosome 21), supporting the 
view that DMI34 can specifically engage with the Dp427m promoter. Surprisingly, DME45 could 
not interact with Dp427m promoter (Figs. 4E and 4F). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 18 
 
Fig. 4: DMI34 establishes physical contacts with the Dp427m promoter in vivo. Chromosome Conformation 
Capture (3C) was applied to detect physical interaction between Intron 34 and Dp427m promoter or Exon 45 and 
Dp427m Promoter. A) Experimental design of 3C between the dystrophin muscle promoter and Intron 34. XbaI 
restriction enzyme was used. 3C on Dp427m and intron 34 were carried out in SJCRH30 (B) and HeLa cells (C). D) 
Experimental design of 3C between the dystrophin muscle promoter and Exon 45. BglII restriction enzyme was used. 
3C on Dp427m and Exon 45 was carried out in SJCRH30 (E) and HeLa cells (F).  After ligation, DNA was purified and 
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specific interactions were detected using specific Taqman probes. To estimate the frequency of random collision 
between digested fragments, two intra-chromosomal (ChX-p21 and ChX-q22) and one inter-chromosomal (Ch 21) 
interactions were analysed. As negative controls, not cross-linked cells were used.  PCR products were then loaded on 
an agarose gel, each panel is representative of four independent experiments. 
 
3.5 Consequences of intron 34 or exon 45 deletion in BMD patients. 
To understand whether DMI34 and DME45 exert a critical role in the regulation of muscle 
dystrophin in patients affected by dystrophinopathies, we analyzed the amount of dystrophin protein 
and transcript in BMD. The dystrophin protein in these BMD patients is shorter, as consequence of 
in frame deletions and is therefore expressed in muscle preserving most of its normal functions [28]. 
Nine patients clinically diagnosed with BMD were selected and grouped according to deletions 
comprising exon 34/intron 34 (Model 34), exon 45 (Model 45), both exons 34/intron 34 and 45 
(Model 34-45) or none of the two regions (control Becker group). We identified only one patient for 
Model 34-45, since these deletions are rare in BMD phenotype. All patients’ deletions were verified 
by microfluidic RealTime-PCR testing the exon-exon junctions of mature DMD mRNA. An 
example of that is shown in Fig. S9. Patients' phenotypes, and how they were grouped, are listed in 
Table 1.  
Next, dystrophin protein levels were assessed in all nine BMD patients and one healthy individual, 
used as a control by Western Blotting on Odyssey employing the Dys2 (last 17 C-terminal amino 
acids) antibody. Fragments of the dystrophin protein were detected in all patients at the expected 
molecular mass and consistently with the corresponding deletions (Fig. 5A). Semi-quantitative 
analysis in these patients revealed that Model 34 had a mean dystrophin expression of 64% (SD ± 
7.1) of the control, while Model 45 and Model 34-45 patients had 18% (SD ± 9.3) and 21%, 
respectively. Protein levels in patients carrying deletions in other regions of the DMD gene were 
quite variable, ranging from 26% (deletion 14-18) to 71% (deletion 50-52) of control (Fig. 6B).  
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Table 1: Description of deletions and patient features whose muscle samples were employed in this study. 
 
 
Patient 
ID 
Deletion 
Age at 
last 
examination 
(years) 
Age at 
time of 
sample 
collection 
(years) 
Clinical 
Diagnosis 
Symptoms 
at last 
neurological 
evaluation 
Dilated 
cardiomyopathy 
Severity 
1 5727 17-44 11 11 
High creatine 
kinase 
asymptomatic no  
2 5348 32-44 41 23 
High creatine 
kinase 
2 episodes of 
suspected 
myoglobinuria 
mild 
weakness 
shoulders 
girdle 
no Very mild 
3 3239 13-34 6 6 Myopathy 
proximal 
muscle 
weakness 
no  
4 3377 41-48 11 11 
High creatine 
kinase 
? no  
5 5993 45-48 13 13 Myopathy ? no  
6 9108 45-47 39 36 
Dilated 
cardiomyopathy 
(FE24%) 
with ICD 
High creatine 
kinase 
Fatigue in 
running 
Mild 
weakness of 
hip girdle and 
of lower 
limbs 
proximal 
muscles 
yes severe 
7 5648 14-53 18 5 
High creatine 
kinase 
Mild 
weakness of 
hip girdle, 
Achilles 
tendon 
retraction and 
scoliosis 
yes (FE 48%) mild 
8 8097 50-52 4 4 
High creatine 
kinase 
normal no asyptomatic 
9 10613 14-18 
29 
(d.o.b. 
01/1983) 
28 
High creatine 
kinase at 3 yrs; 
EMG: normal; 
Echocardiogram: 
normal: 
Under treatment 
with 
levetiracetam 
(epilepsy); 
Pain and stiffness 
in the lower 
limbs; 
Family history of 
cardiomyopathy 
and BMD 
normal no asyptomatic 
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Fig. 5. Western Blot analysis of dystrophin expression in patients with Becker Muscular Dystrophy. A) Western 
blot of total protein extracts from skeletal muscle biopsy of patients and control. Blots were probed with the Dys2 
antibody for dystrophin and a sarcomeric alpha-actinin antibody as a loading control. B) Western blot semi-
quantification using ImageJ software. Data were normalized to alpha-actinin and both individual and grouped patients 
were showed as per cent of control. Values for the grouped patients’ graph are expressed as means ± SD. 
 
4 Discussion 
4.1 A new DMD RNA pol II pausing site 
In this study we have, for the first time, analyzed the dynamics by which the RNA pol II passes 
through the DMD locus in the context of specific histone marks. We identified a unique pausing site 
in intron 52 out of the 2,2 Mb encompassing the DMD locus, demonstrating that the RNA 
polymerase displays an extraordinary level of processivity in this huge locus, nevertheless 
recognizes the need to stop during its processivity. This is the first report of an internal pausing site 
in the dystrophin gene. Following transcription initiation, RNA pol II can enter into a paused or 
stalled status generally immediately downstream the transcription start site before starting a 
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productive elongation. This is a widespread physiologically regulated phenomenon, though not 
completely understood, and RNA pol II reactivation occurs via a number of elongation complexes, 
[29]. 
RNA polymerase II pausing sites are indeed located just downstream of the promoter in a relevant 
proportion of human genes, and not in other regions. The DMI52 site is within an intron, positioned 
in the central part of the DMD gene. Although DMD has several promoters, DMI52 is not located 
in close proximity to any 3’ DMD promoter regions, since Dp114 is driven by a promoter in intron 
44 with the ATG codon in exon 51, whereas Dp140 has promoter and unique first exon in intron 55. 
Regions annotated as RNA pol II pausing sites have some sequence characteristics as binding 
motifs for transcription factors, generally GC rich regions and presence of G4 (RNA G-
quadruplexes) motifs, which are transcriptional and epigenetic regulatory targets of transcription 
factors. These last have been recently connected to human diseases as amyotrophic lateral sclerosis 
[30]. The RNA polymerase II pausing is tightly associated with pre-mRNA processing being both 
co-transcriptional processes [31]. Recently, a relevant role of RNA loops (R-loops) in facilitating 
RNA pol II pausing prior elongation has been pinpointed, and it is mediated by intense antisense 
transcription over the pausing elements [31]. The functional meaning of this DMD intron 52 
pausing site is unknown, especially considering its unusual location. It might have a role in 
controlling the efficiency of transcription initiation and also in regulating alternative splicing. The 
DMD locus is alternatively spliced, and many lncRNAs are actively transcribed, especially around 
the region of the intron52 pausing site (from intron 45 to intro 55) [13]. Indeed, we describe here an 
additional new lncRNA within intron 62. We can hypothesize that this might be a crucial region for 
the dystrophin transcriptional dynamics regulation, requiring a pausing site and then restarting 
elongation downstream. Since R-loops also promote chromatin architecture shaping, which controls 
termination region, this region might also be implicated in gene transcription termination and 
polyadenylation regulation [32, 33]. Very recently ultra-deep transcript sequencing analyses have 
shown that dystrophin pre-mRNA undergoes multi-step non-sequential splicing thus suggesting a 
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highly regulated process in which control of RNA pol II processivity may be critical [34]. These 
authors described in deep detail the intron removal dynamic of the DMD gene identifying non-
consecutive intron removal and exon blocks, as result of 3 or more joined exons flanked by 
unspliced introns. Interestingly, the two blocks containing exons 50-52 and 53-57 are spliced non 
sequentially, with a recursive splicing occurring within intron 52.  This may reinforce the regulatory 
role this intron 52 exerts in transcription dynamics. 
 
4.2 A novel lncRNA.  
The ChIP-on chip analyses also revealed the presence of a new promoter nearby exon 62 which 
drives trasncription of a lnc-RNA (lncRNA62int) expressed in rhabdomyosarcoma cells. We did not 
pick up lncRNA62int in our previous study [13], but it is possible that this new lncRNA might be 
more represented in rhabdomyosarcoma than in normal skeletal muscle, and therefore it can have 
escaped our previous analysis. Indeed, an alternatively spliced isoform of this lncRNA has been 
also annotated in a published  chondrosarcoma RNA library suggesting that this type of lncRNA 
may be typically expressed in tumour tissues/cells. Again, this new lncRNA62int underlines the 
intense transcriptional activity, which occurs in this region of the DMD gene.  
 
4.2 Intron 34 dystrophin enhancer (DMI34) 
Our epigenetic analysis has identified two putative transcriptional cis-DNA elements that may 
contribute to the regulation of the DMD locus. More specifically, we have mapped two DNA 
sequences involved in the architectural organization of the locus. Intron 34 can establish a physical 
contact with the muscle specific promoter most likely through formation of a large loop resulting 
from bridging two regions that are about 800 Kbs apart as suggested by chromosome conformation 
capture data.  The analyses of this region in the context of a Luciferase assay suggest that it can 
stimulate the expression of the Dp427m mRNA isoform.  The fact that such transcriptional 
stimulation is driven by the sequence in both orientations and that it is marked by strong acetylation 
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of H3K27 favors the idea that indeed the intron 34 region can function as a distal transcriptional 
enhancer. This finding is also supported by the observation that transcript levels of the DMD gene 
are lower in BMD patients carrying genomic deletions encompassing the intron 34 (Model 34). 
Conversely, in vitro assays did not support a transcriptional regulatory role for DME45.  BMD 
patients deleted in this region have lower levels of dystrophin protein as compared to muscle 
samples with deletion of exon 34.  Of course, this variability could be due to the different extent of 
the deletion in these two groups (many other exons are indeed missing). Therefore, we cannot 
conclude about the possible function DME45 has, and further studies are required to elucidate its 
eventual role. 
Our results highlight a profound complexity in the DMD gene epigenetic structure and unveil new 
transcriptional dynamics. We showed for the first time a genuine RNA pol II pausing site, 
interestingly not located adjacent to the promoter region. 
We identified the new DME34 enhancer, which is interesting also for therapeutic implications. 
Indeed, modulation of the DME34 may enhance DMD transcript production with beneficial effect 
in terms of protein amount production thereby also possible applicable to BMD patients, currently 
orphan of any specific treatment [7]. 
In conclusion, our findings have started to provide a global picture on how the entire DMD locus is 
epigenetically assembled and dynamically transcribed by the RNA pol II.  
These findings are important for elucidating the basic mechanisms, the DMD gene follows when 
physiologically expressed, and may contribute to a better understanding of disease severity 
pathogenesis in both BMD and DMD patients.  
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